Skip to main content
. 2021 Oct 25;11:701736. doi: 10.3389/fonc.2021.701736

Figure 10.

Figure 10

Combined analysis of H2AFZ expression and TP53 status improves prognostic value of HCC patient outcome. (A) Overall survival and progression-free survival of TP53mut and TP53wt patients. (B) Overall survival and progression-free survival of the four subgroups (G1: H2AFZhigh/TP53mut; G2: H2AFZhigh/TP53wt; G3: H2AFZlow/TP53mut; G4: H2AFZlow/TP53wt). (C) Expression levels of immune-checkpoint-relevant transcripts in the four subgroups, respectively *p < 0.05; **p < 0.001; ***p < 0.0001; ns, not significant.